To identify potential active ingredients in SM injection for IPF treatment, we conducted molecular docking on the 16 components, using the 3 core therapeutic targets (MMP9, IL-6, and TNF-α) as receptors. This evidence concerns the gene IL6 and idiopathic pulmonary fibrosis.